Search

LivingCells accelerates those biomedical and biotech projects and startups, whose objectives are the development of new therapies, new mechanisms of diagnosis and prognosis of diseases, as well as the

Efficacy results of the double-blind placebo-controlled trial will be available by the end of 2024.

With the mission to revolutionize the way drugs are discovered, the company has pioneered two cutting-edge technological platforms: KINETICfinder® and COVALfinder®.

At Cocoon Bioscience, we offer a different alternative, orthogonal approach, wherein we use insect chrysalis at its cocoon stage as natural bioreactors to express enzymes, growth factors, and other

As a novelty in this call, AseBio will consider expressions of interest for multi-year candidacies for the 2025-2029.

Meet Cocoon Bioscience, our new member. We talked to its Romy Dalton, COO & CSO.

Algenex states that current production methods for recombinant proteins present “a series of challenges in respect to development speed, scalability, technical complexity, and cost”.

Bioenergy, biofuels, biological treatment of waste and wastewater, reduction of atmospheric emissions, or improvement of energy efficiency are just some examples of the responses offered by the

The startup Roka Furadada, with laboratories in the Barcelona Science Park, has donated a first batch of sun protection creams to the Hospital del Mar in Barcelona for the intensive care unit (ICU)

The project will reinforce the leading role of the University of Barcelona in biomedical research, especially due to its connection with a reference space such as the Barcelona Science Park, the

Meet ICON, our new member. We talked to its Pedro Vinals, Vice President, General Partner.

Following the vote on February 7th, the European Parliament will be able to initiate negotiations with the Member States for the creation of the definitive law.

Meet Savana, our new member. We talked to its Antonio Urda, chief government affairs officer.

According to the amendment proposal, the transition period is only extended for manufacturers with ongoing contracts with notified bodies.

The Parliament is expected to adopt its mandate during the plenary session on February 7, 2024, after which it will be ready to commence negotiations with EU Member States.

GENESIS Tech Transfer Boost is an investment vehicle created in 2022 that invests in the field of Biomedicine.

Keystone Symposia Epigenetic Mechanisms and Cancer Treatment; Bio-Neuroscience; 17º Annual European Life Sciences CEO Forum and BIO-Europe Spring 2024.

On World Cancer Day, we take a look at the role that biotechnology has played in recent years in crucial areas related to cancer.

Affirma Biotech develops immune system activation compounds for the treatment of infectious diseases.

Through this combination, the Group will become one of the main independent European bio-CDMOs, with gross sales above €75m.

Meet Afarvi Sistemas, our new member. We talked to its Juan Antonio de la Cuerda Pérez, responsable de Desarrollo de Negocio y Marketing.